- Home
- CLRB vs AIMD Comparison
CLRB vs AIMD Comparison
Compare CLRB & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLRB
- AIMD
- Stock Information
- Founded
- CLRB 2002
- AIMD 1984
- Country
- CLRB United States
- AIMD United States
- Employees
- CLRB N/A
- AIMD N/A
- Industry
- CLRB Biotechnology: Pharmaceutical Preparations
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- CLRB Health Care
- AIMD Health Care
- Exchange
- CLRB Nasdaq
- AIMD Nasdaq
- Market Cap
- CLRB 14.2M
- AIMD 11.9M
- IPO Year
- CLRB N/A
- AIMD N/A
- Fundamental
- Price
- CLRB $4.44
- AIMD $3.26
- Analyst Decision
- CLRB Hold
- AIMD
- Analyst Count
- CLRB 2
- AIMD 0
- Target Price
- CLRB N/A
- AIMD N/A
- AVG Volume (30 Days)
- CLRB 113.2K
- AIMD 7.1M
- Earning Date
- CLRB 08-14-2025
- AIMD 08-22-2025
- Dividend Yield
- CLRB N/A
- AIMD N/A
- EPS Growth
- CLRB N/A
- AIMD N/A
- EPS
- CLRB N/A
- AIMD N/A
- Revenue
- CLRB N/A
- AIMD $106,207.00
- Revenue This Year
- CLRB N/A
- AIMD N/A
- Revenue Next Year
- CLRB N/A
- AIMD N/A
- P/E Ratio
- CLRB N/A
- AIMD N/A
- Revenue Growth
- CLRB N/A
- AIMD 13.38
- 52 Week Low
- CLRB $4.36
- AIMD $2.00
- 52 Week High
- CLRB $68.70
- AIMD $5.00
- Technical
- Relative Strength Index (RSI)
- CLRB 35.40
- AIMD 62.08
- Support Level
- CLRB $4.72
- AIMD $2.25
- Resistance Level
- CLRB $5.09
- AIMD $3.64
- Average True Range (ATR)
- CLRB 0.38
- AIMD 0.34
- MACD
- CLRB 0.09
- AIMD 0.08
- Stochastic Oscillator
- CLRB 3.42
- AIMD 44.89
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.